Showing results (11-20 of 17) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Bioorganic & Medicinal Chemistry Letters|February 6, 2008
2,6-Diaryl-4-phenacylaminopyrimidines as potent and selective adenosine A(2A) antagonists with reduced hERG liabilityManisha Moorjani, Xiaohu Zhang, Yongsheng Chen, et al.Bioorganic & Medicinal Chemistry Letters|March 11, 2008
Synthesis of N-pyrimidinyl-2-phenoxyacetamides as adenosine A2A receptor antagonistsXiaohu Zhang, Jaimie K Rueter, Yongsheng Chen, et al.Journal of Medicinal Chemistry|January 15, 2008
Identification of novel, water-soluble, 2-amino-N-pyrimidin-4-yl acetamides as A2A receptor antagonists with in vivo efficacyDeborah H Slee, Xiaohu Zhang, Manisha Moorjani, et al.Journal of Medicinal Chemistry|March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 1. Structure-activity relationships and optimization of heterocyclic substituentsDeborah H Slee, Yongsheng Chen, Xiaohu Zhang, et al.Journal of Medicinal Chemistry|October 25, 2008
Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's diseaseXiaohu Zhang, John E Tellew, Zhiyong Luo, et al.Journal of Medicinal Chemistry|January 15, 2009
N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacyMarion C Lanier, Manisha Moorjani, Zhiyong Luo, et al.Journal of Medicinal Chemistry|March 1, 2008
2-Amino-N-pyrimidin-4-ylacetamides as A2A receptor antagonists: 2. Reduction of hERG activity, observed species selectivity, and structure-activity relationshipsDeborah H Slee, Manisha Moorjani, Xiaohu Zhang, et al.Pageof 2